[go: up one dir, main page]

BRPI0819719B8 - compostos de inibição de dipeptidil peptidase-iv, métodos de preparação dos mesmos, e preparações farmacêuticas contendo os mesmos como agente ativo - Google Patents

compostos de inibição de dipeptidil peptidase-iv, métodos de preparação dos mesmos, e preparações farmacêuticas contendo os mesmos como agente ativo

Info

Publication number
BRPI0819719B8
BRPI0819719B8 BRPI0819719A BRPI0819719A BRPI0819719B8 BR PI0819719 B8 BRPI0819719 B8 BR PI0819719B8 BR PI0819719 A BRPI0819719 A BR PI0819719A BR PI0819719 A BRPI0819719 A BR PI0819719A BR PI0819719 B8 BRPI0819719 B8 BR PI0819719B8
Authority
BR
Brazil
Prior art keywords
methods
active agent
dipeptidyl peptidase
pharmaceutical preparations
preparations containing
Prior art date
Application number
BRPI0819719A
Other languages
English (en)
Inventor
Lee Chang-Seok
Min Changhee
Bong Lee Hee
Joo Yim Hyeon
Lee Jaeick
Kim Kyoung-Hee
Woong Lee Kyu
Lee Sung-Hack
Su Park Wan
Original Assignee
Lg Chemical Ltd
Lg Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lg Chemical Ltd, Lg Life Sciences Ltd filed Critical Lg Chemical Ltd
Publication of BRPI0819719A2 publication Critical patent/BRPI0819719A2/pt
Publication of BRPI0819719A8 publication Critical patent/BRPI0819719A8/pt
Publication of BRPI0819719B1 publication Critical patent/BRPI0819719B1/pt
Publication of BRPI0819719B8 publication Critical patent/BRPI0819719B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

compostos de inibição de dipeptidil peptidase-iv, métodos de preparação dos mesmos, e preparações farmacêuticas contendo os mesmos como agente ativo. novos compostos de fórmula (1) são descritos aqui como definidos na especificação dotados de excelente atividade inibitória contra dipeptidil peptidase-iv (dpp-v), métodos de preparação dos mesmos e composições farmacêuticas compreendendo os mesmos como um agente ativo.
BRPI0819719A 2007-12-21 2008-12-19 compostos de inibição de dipeptidil peptidase-iv, métodos de preparação dos mesmos, e preparações farmacêuticas contendo os mesmos como agente ativo BRPI0819719B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20070134887 2007-12-21
KR10-2007-0134887 2007-12-21
PCT/KR2008/007543 WO2009082134A2 (en) 2007-12-21 2008-12-19 Dipeptidyl peptidase-iv inhibiting compounds, methods of preparing the same, and pharmaceutical compositions containing the same as active agent

Publications (4)

Publication Number Publication Date
BRPI0819719A2 BRPI0819719A2 (pt) 2015-06-16
BRPI0819719A8 BRPI0819719A8 (pt) 2015-09-22
BRPI0819719B1 BRPI0819719B1 (pt) 2020-09-24
BRPI0819719B8 true BRPI0819719B8 (pt) 2021-05-25

Family

ID=40801676

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0819719A BRPI0819719B8 (pt) 2007-12-21 2008-12-19 compostos de inibição de dipeptidil peptidase-iv, métodos de preparação dos mesmos, e preparações farmacêuticas contendo os mesmos como agente ativo

Country Status (14)

Country Link
US (1) US8470836B2 (pt)
EP (1) EP2220086A4 (pt)
JP (1) JP5358585B2 (pt)
KR (1) KR101105607B1 (pt)
CN (1) CN101903386B (pt)
AU (1) AU2008341352B2 (pt)
BR (1) BRPI0819719B8 (pt)
CA (1) CA2710109C (pt)
CO (1) CO6300861A2 (pt)
EA (1) EA201070635A1 (pt)
MA (1) MA31919B1 (pt)
UA (1) UA103181C2 (pt)
WO (1) WO2009082134A2 (pt)
ZA (1) ZA201004214B (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
CN103080088B (zh) * 2010-09-03 2014-09-24 株式会社Lg生命科学 用于合成药物的中间体化合物的制备方法
CN102617566B (zh) * 2011-01-30 2015-03-04 山东轩竹医药科技有限公司 吡啶并咪唑烷衍生物
CN102875567B (zh) * 2011-07-15 2015-03-11 天津药物研究院 一类含哌嗪化合物、制备及用途
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
CN104159884B (zh) * 2012-02-03 2016-01-13 株式会社Lg生命科学 通过使用水或多种酸作为添加剂的新型麦克尔加成反应制备化合物的方法
CN105142621A (zh) 2012-10-24 2015-12-09 国家健康科学研究所 用于预防或治疗糖尿病和促进β-细胞存活的TPL2激酶抑制剂
CN105017244A (zh) * 2014-04-16 2015-11-04 上海药明康德新药开发有限公司 顺反叔丁基-4-氧六氢化-1H-吡咯[3,4-c]吡啶-2(3H)-羧酸叔丁酯的合成方法
CN104447511A (zh) * 2014-11-12 2015-03-25 江苏中邦制药有限公司 一种n-叔丁氧羰基-3-哌啶酮的合成方法
WO2016151018A1 (en) 2015-03-24 2016-09-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Method and pharmaceutical composition for use in the treatment of diabetes
KR102184129B1 (ko) * 2017-11-16 2020-11-27 주식회사 엘지화학 의약품 합성용 중간체 화합물의 제조 방법
WO2023150619A2 (en) * 2022-02-02 2023-08-10 The Katholieke Universiteit Leuven Tetrahydropyridopyrimidines and related analogs for inhibiting yap/taz-tead
CN118791425A (zh) * 2024-06-18 2024-10-18 浙江尚科生物医药有限公司 一种1-boc-3-哌啶酮及其类似环酮类化合物的合成方法
CN120004890B (zh) * 2025-02-17 2025-10-21 安徽峆一药业股份有限公司 一种吉格列汀盐酸盐微晶及其制备方法与应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CO5150173A1 (es) 1998-12-10 2002-04-29 Novartis Ag Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
UA74912C2 (en) 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
US6861440B2 (en) 2001-10-26 2005-03-01 Hoffmann-La Roche Inc. DPP IV inhibitors
EP1490335B1 (en) * 2002-03-25 2007-09-19 Merck & Co., Inc. Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
US7265128B2 (en) 2003-01-17 2007-09-04 Merck & Co., Inc. 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
WO2004089362A1 (en) * 2003-04-11 2004-10-21 Novo Nordisk A/S 2-cyanopyrroles and their analogues as ddp-iv inhibitors
TWI357902B (en) * 2005-04-01 2012-02-11 Lg Life Science Ltd Dipeptidyl peptidase-iv inhibiting compounds, meth

Also Published As

Publication number Publication date
CO6300861A2 (es) 2011-07-21
AU2008341352B2 (en) 2013-08-01
BRPI0819719A2 (pt) 2015-06-16
WO2009082134A3 (en) 2009-09-24
US20100274013A1 (en) 2010-10-28
EP2220086A2 (en) 2010-08-25
MA31919B1 (fr) 2010-12-01
US8470836B2 (en) 2013-06-25
BRPI0819719B1 (pt) 2020-09-24
CN101903386A (zh) 2010-12-01
CA2710109A1 (en) 2009-07-02
AU2008341352A1 (en) 2009-07-02
JP2011507832A (ja) 2011-03-10
WO2009082134A2 (en) 2009-07-02
EP2220086A4 (en) 2010-12-22
BRPI0819719A8 (pt) 2015-09-22
JP5358585B2 (ja) 2013-12-04
CN101903386B (zh) 2015-04-22
EA201070635A1 (ru) 2010-12-30
KR20090068156A (ko) 2009-06-25
ZA201004214B (en) 2011-04-28
KR101105607B1 (ko) 2012-01-18
CA2710109C (en) 2016-07-19
UA103181C2 (ru) 2013-09-25

Similar Documents

Publication Publication Date Title
BRPI0819719B8 (pt) compostos de inibição de dipeptidil peptidase-iv, métodos de preparação dos mesmos, e preparações farmacêuticas contendo os mesmos como agente ativo
BR112014007163A2 (pt) composições farmacêuticas de n-metil-2 [3 ((e)-2 piridin-2 il-vinil)-1h-indazol-6 ilsulfanil]-benzamida
GEP20125469B (en) Inhibitors of akt activity
BRPI0418251C1 (pt) fosfonatos, monofosfonamidatos, bisfosfonamidatos, e, composição farmacêutica os compreendendo
MX336381B (es) Boronatos como inhibidores de arginasa.
NI200700064A (es) Nuevas composiciones farmacéuticas que comprenden ácido 4-(4-(3-(4-cloro-3- trifluorometil-fenil)- ureido)-3-fluoro-fenoxi)-piridin-2-carboxílico para el tratamiento de trastornos hiperproliferativos.
MX2009010047A (es) Compuestos quimicos.
GEP20156309B (en) Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
EA021275B9 (ru) Гетероциклические соединения, содержащая их фармацевтическая композиция и их применение для лечения pask-опосредованного заболевания
MX2009010045A (es) Compuestos quimicos.
AU2011338389A8 (en) Bicyclic compounds as Pim inhibitors
UY30819A1 (es) Derivados de pirazol, composiciones farmacéuticas conteniéndolos, procesos de preparacion y aplicaciones
BR112015016001A2 (pt) compostos, composições farmacêuticas e respectivos usos e método para tratar ou prevenir infecção bacteriana
BR112012015755A2 (pt) lipideos composicoes de lipideos, e metodos de uso dos mesmos
BR112012027062A2 (pt) composto, processo para a preparação de um composto, método para prevenção e/ou tratamento de doenças e condições, e, composição farmacêutica
BRPI0514665A2 (pt) compostos com atividade antibacteriana, composições farmacêuticas e uso dos mesmos
TW200745103A (en) Substituted 7-azaindazoles, compositions containing them, production process and use
PH12013502262A1 (en) Spiro-[1,3]-oxazines and spiro-[1,4]-oxazepines as bace1 and/or bace2 inhibitors
BRPI0821004A8 (pt) Composto derivado de aminopirazol, composição farmacêutica que o contem e uso deste
WO2009082152A3 (en) Glucokinase activators and pharmaceutical compositions containing the same as an active ingredient
MX2009007337A (es) Indazoles sustituidos con 5-piridinona.
WO2009036341A3 (en) Compositions and methods relating to hiv protease inhibition
WO2011159129A3 (ko) 신규한 로다닌 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 ａｉｄｓ 예방 또는 치료용 약학 조성물
NZ592429A (en) PHENANTHROINDOLIZIDINE DERIVATIVE AND NFkB INHIBITOR CONTAINING SAME AS ACTIVE INGREDIENT
WO2009105969A8 (zh) 埃坡霉素类似物、其药物组合物、用途及其制备方法

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B25A Requested transfer of rights approved

Owner name: LG CHEM, LTD. (KR)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 24/09/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 19/12/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF